RCS - Poolbeg Pharma PLC - POLB 001 Patent Granted in Korea

Poolbeg PharmaAnnouncement

20/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250320:nRST4632Ba&default-theme=true

RNS Number : 4632B  Poolbeg Pharma PLC  20 March 2025

Poolbeg Pharma plc

 

POLB 001 Patent Granted in Korea

 

Grant further strengthens Poolbeg's global intellectual property ("IP")
portfolio

 

20 March 2025 - Poolbeg Pharma
(https://url.avanan.click/v2/___https:/www.poolbegpharma.com/___.YXAxZTpzaG9yZWNhcDphOm86MDEyNWViMjlmNzZkZWZiMmRjNTc2MjQ5ZTRkN2Q1YjM6NjozYmY0OmJiMDhkZWIyZjlkYjAxNDhhMmNkMmZhZTgyOGI2ZTI3MjgwYTVmYjdmOTk5YjRjYjVjNDBjMDAyMzVmOGRjM2U6cDpGOk4)
 (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical
company focussed on the development of innovative medicines to address unmet
medical needs, announces that the Korean Intellectual Property Office has
notified the Company of its official decision to grant Poolbeg's Republic of
Korea Immunomodulator II patent application providing protection to POLB 001
for the treatment of severe influenza to December 2038.

POLB 001 is a potent and selective p38 MAP kinase inhibitor with strong
potential across multiple disease areas, including the prevention and
treatment of cancer immunotherapy-induced Cytokine Release Syndrome ("CRS")
and severe influenza. POLB 001 holds the potential to address significant
unmet needs affecting patients and healthcare systems globally. This patent
grant further strengthens Poolbeg's IP portfolio.

Poolbeg has a robust portfolio of patents in place covering p38 MAP kinase
inhibitors for the treatment of severe influenza; and for POLB 001 for the
prevention or treatment of hypercytokinemia. Additional patent applications
have been filed to strengthen and complement Poolbeg's POLB 001 patent
portfolio, particularly for cytokine release syndrome caused by cancer
immunotherapies. Developing a strong intellectual property portfolio remains a
key priority for Poolbeg, enhancing POLB 001's value and appeal to potential
partners.

Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg, commented: "This
latest patent grant reflects our commitment to further strengthening POLB
001's global IP portfolio, enhancing its value and attractiveness to
prospective partners. As a Phase 2 ready oral  therapy, POLB 001 holds the
potential to significantly benefit patients and healthcare systems globally,
and this patent represents another step forward in our mission to positively
impact the lives of patients."

Enquiries

 

 Poolbeg Pharma Plc                                                  +44 (0) 207 183 1499

 Jeremy Skillington, CEO                                             ir@poolbegpharma.com

 Ian O'Connell, CFO

  
 Cavendish Capital Markets Ltd (NOMAD & Joint Broker)                +44 (0) 207 220 0500

 Geoff Nash, Camilla Hume, Trisyia Jamaludin (Corporate Finance)

 Nigel Birks (Life Science Specialist Sales)

 Harriet Ward (ECM)

  
 Shore Capital Stockbrokers Ltd (Joint Broker)                       +44 (0) 207 408 4090

 David Coaten, Harry Davies-Ball (Corporate Advisory)

Malachy McEntyre, Isobel Jones (Corporate Broking)

 J&E Davy (Joint Broker)                                             +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

  
 Optimum Strategic Communications                                    +44 (0) 208 078 4357

 Nick Bastin, Vici Rabbetts, Elena Bates                             poolbeg@optimumcomms.com (mailto:poolbeg@optimumcomms.com)

  

About Poolbeg Pharma plc

Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focussed on
the development of innovative medicines to address unmet medical needs.
Poolbeg comprises a strong and growing portfolio of development assets.

 

For more information, please go to www.poolbegpharma.com
(http://www.poolbegpharma.com)  or follow us on Twitter
(https://url.avanan.click/v2/___https:/twitter.com/PoolbegPharma___.YXAxZTpzaG9yZWNhcDphOm86MDEyNWViMjlmNzZkZWZiMmRjNTc2MjQ5ZTRkN2Q1YjM6NjphMmQ2OmZhNGMwMmExOWVkOGRjZDBkY2MyMGRiYTk3MTY2YjliYzU1ZjM4MTg1NjAxZTZjNmQwN2UyNjI2NmQ0M2RkNzk6cDpGOk4)
 and LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/poolbeg-pharma/___.YXAxZTpzaG9yZWNhcDphOm86MDEyNWViMjlmNzZkZWZiMmRjNTc2MjQ5ZTRkN2Q1YjM6NjozNGNlOjVjNTk4MTc1NmY1YjA3YWNlMGI3NjkzZDFhNWExZjVkYjhjNzcyZDlhZmE1OTY4ZWQ0M2Q0Y2JjM2JiZGQ1OTM6cDpGOk4)
 @PoolbegPharma.

 

Forward-Looking Statements

This announcement may contain forward-looking statements and the words
"expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast",
"project" and similar expressions (or their negative) identify certain of
these forward-looking statements. The forward-looking statements in this
announcement are based on numerous assumptions and Poolbeg's present and
future business strategies and the environment in which Poolbeg expects to
operate in the future. Forward-looking statements involve inherent known and
unknown risks, uncertainties and contingencies because they relate to events
and depend on circumstances that may or may not occur in the future and may
cause the actual results, performance or achievements to be materially
different from those expressed or implied by such forward-looking statements.
These statements are not guarantees of future performance or the ability to
identify and consummate investments. Many of these risks and uncertainties
relate to factors that are beyond Poolbeg's ability to control or estimate
precisely, such as future market conditions, currency fluctuations, the
behaviour of other market participants, the outcome of clinical trials, the
actions of regulators and other factors such as Poolbeg's ability to obtain
financing, changes in the political, social and regulatory framework in which
Poolbeg operates or in economic, technological or consumer trends or
conditions. Past performance should not be taken as an indication or guarantee
of future results, and no representation or warranty, express or implied, is
made regarding future performance. No person is under any obligation to update
or keep current the information contained in this announcement or to provide
the recipient of it with access to any additional relevant information.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAJMMFTMTATMMA